Phase 1 Bipolar Disorder Trial, Recruiting NCT03522545 Sponsor: The University of Texas Health Science Center, Houston Condition: Bipolar Disorder
Back to Bipolar Disorder

Phase 1 Bipolar Disorder Trial, Recruiting

NCT03522545
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Bipolar I or Bipolar II disorder, confirmed through a structured clinical interview
  • People between 18 and 65 years of age
  • People currently experiencing a depressive episode that scores 25 or above on a standard depression rating scale (MADRS)
  • People whose depression has not responded to at least two previous medication trials (across their lifetime) using mood stabilisers or antidepressants — where each trial lasted at least 6 weeks at an appropriate dose, or where the person was unable to complete a 6-week trial
  • People with a blood inflammation marker (CRP) measured above 5 mg/L
  • Female participants who are not pregnant, not breastfeeding, and not planning to become pregnant during the study, and who are using a reliable form of contraception if they are of childbearing age
  • People who a clinician considers capable of giving informed consent
  • People who have signed a written consent form
  • People who are sufficiently fluent in English to complete cognitive and psychological testing

Who may not be able to join:

  • People who have had a stem cell (MSC) transplant within the last six months
  • People who would be unable to follow the study procedures
  • People whom a clinician considers to be at high risk of suicide
  • People with a history of brain injury, neurological conditions, seizure disorders requiring medication, significant kidney problems, significant liver problems, a weakened immune system, HIV, removal of the spleen, or cancer
  • People with unstable serious physical health conditions, including abnormal lab results, or conditions that affect cognitive testing such as Parkinson's disease, multiple sclerosis, stroke, or alcohol and substance use disorders
  • People with other serious medical conditions that, in the investigator's opinion, are not adequately managed and would prevent safe participation in the trial
  • People who have unstable blood pressure or circulation at the time of the stem cell infusion
  • People who test positive for pregnancy at the screening or baseline visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jair C Soares, MD, PhD, The University of Texas Health Science Center, Houston

Phone: (713) 486-2523

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
20 April 2022
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov